Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor

Alberto Radaelli1, Claudia Loardi, Maria Cazzaniga

  • 1Divisione di Riabilitazione Cardiologica - Ospedale San Gerardo, Via Pergolesi, 33, 20052 Monza, Italy.

Insights

High-dose statins and ACE-inhibitors significantly reduce the inflammatory response after coronary artery bypass graft (CABG) surgery. This early treatment with high doses of these cardiovascular drugs almost completely prevents the intense systemic inflammation associated with CABG.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • On-pump coronary artery bypass graft (CABG) surgery can trigger an inflammatory response (IR) that may impair revascularization.
  • Understanding the temporal profile of this IR and potential pharmaceutical interventions is crucial for improving patient outcomes.

Purpose of the Study:

  • To characterize the temporal profile of the inflammatory response during CABG surgery by measuring markers in systemic and coronary blood.
  • To determine if cardiovascular drugs with anti-inflammatory properties, specifically statins and ACE-inhibitors (ACEI), can inhibit this response and at which doses.

Main Methods:

  • A randomized study involving 22 patients scheduled for CABG, assigned to standard-dose (STD) or high-dose (HiDo) statin/ACEI combination therapy.
  • Serial plasma assays (IL-6, TNF-alpha, E-selectin, vWF, sVCAM-1) from arterial, venous, and coronary sinus blood before, during, and after CABG.
  • Myocardial perfusion scans before and 2 months post-surgery.

Main Results:

  • Standard-dose (STD) treatment showed significant increases in IL-6 and TNF-alpha post-surgery, irrespective of blood sampling site.
  • High-dose (HiDo) treatment drastically attenuated these inflammatory marker increases.
  • Myocardial ischemia scores normalized post-CABG in the HiDo group, but not in the STD group.

Conclusions:

  • On-pump CABG surgery induces a substantial systemic inflammatory response.
  • Early treatment with high doses of ACE-inhibitors and statins can almost completely prevent this inflammatory response.
  • High-dose cardiovascular drug therapy appears to improve myocardial revascularization post-CABG.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...